Skip to main content

Combinations of the azaquinazoline anti- agent, AWZ1066S, with benzimidazole anthelmintics synergise to mediate sub-seven-day sterilising and curative efficacies in experimental models of filariasis.

Frontiers in microbiology

Authors: Shrilakshmi Hegde, Amy E Marriott, Nicolas Pionnier, Andrew Steven, Christina Bulman, Emma Gunderson, Ian Vogel, Marianne Koschel, Alexandra Ehrens, Sara Lustigman, Denis Voronin, Nancy Tricoche, Achim Hoerauf, Marc P Hübner, Judy Sakanari, Ghaith Aljayyoussi, Fabian Gusovsky, Jessica Dagley, David W Hong, Paul O'Neill, Steven A Ward, Mark J Taylor, Joseph D Turner

Lymphatic filariasis and onchocerciasis are two major neglected tropical diseases that are responsible for causing severe disability in 50 million people worldwide, whilst veterinary filariasis (heartworm) is a potentially lethal parasitic infection of companion animals. There is an urgent need for safe, short-course curative (macrofilaricidal) drugs to eliminate these debilitating parasite infections. We investigated combination treatments of the novel anti- azaquinazoline small molecule, AWZ1066S, with benzimidazole drugs (albendazole or oxfendazole) in up to four different rodent filariasis infection models: CB.17 SCID miceMongolian gerbils, Mongolian gerbils, and Mongolian gerbils. Combination treatments synergised to elicit threshold (>90%) depletion from female worms in 5 days of treatment, using 2-fold lower dose-exposures of AWZ1066S than monotherapy. Short-course lowered dose AWZ1066S-albendazole combination treatments also delivered partial adulticidal activities and/or long-lasting inhibition of embryogenesis, resulting in complete transmission blockade in and gerbil models. We determined that short-course AWZ1066S-albendazole co-treatment significantly augmented the depletion of populations within both germline and hypodermal tissues of female worms and in hypodermal tissues in male worms, indicating that anti- synergy is not limited to targeting female embryonic tissues. Our data provides pre-clinical proof-of-concept that sub-seven-day combinations of rapid-acting novel anti- agents with benzimidazole anthelmintics are a promising curative and transmission-blocking drug treatment strategy for filarial diseases of medical and veterinary importance.

Copyright © 2024 Hegde, Marriott, Pionnier, Steven, Bulman, Gunderson, Vogel, Koschel, Ehrens, Lustigman, Voronin, Tricoche, Hoerauf, Hübner, Sakanari, Aljayyoussi, Gusovsky, Dagley, Hong, O'Neill, Ward, Taylor and Turner.

PMID: 38362501

Participating cluster members